{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T22:12:41Z","timestamp":1766441561678},"reference-count":59,"publisher":"American Society of Parasitologists","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Parasitology"],"published-print":{"date-parts":[[2020,5,4]]},"DOI":"10.1645\/19-80","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T09:15:26Z","timestamp":1588151726000},"page":"323","source":"Crossref","is-referenced-by-count":6,"title":["Benznidazole\/Poloxamer 407 Solid Dispersion as a New Strategy to Improve the Treatment of Experimental Trypanosoma cruzi Infection"],"prefix":"10.1645","volume":"106","author":[{"given":"Carolina","family":"Davies","sequence":"first","affiliation":[{"name":"Instituto de Patolog\u00eda Experimental, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anal\u00eda","family":"Simonazzi","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones para la Industria Qu\u00edmica, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Francisco","family":"Micheloud","sequence":"additional","affiliation":[{"name":"Grupo de Trabajo de Patolog\u00eda, Epidemiolog\u00eda e Investigaci\u00f3n Diagn\u00f3stica, \u00c1rea de Sanidad Animal-IIACS Leales\/INTA-Salta, RN 68, km 172, Cerrillos, Salta, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Gabriela","family":"Ragone","sequence":"additional","affiliation":[{"name":"Instituto de Patolog\u00eda Experimental, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia Graciela","family":"Cid","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones para la Industria Qu\u00edmica, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga S\u00e1nchez","family":"Negrette","sequence":"additional","affiliation":[{"name":"C\u00e1tedra de Inmunolog\u00eda, Facultad de Ciencias Agrarias y Veterinarias, Universidad Cat\u00f3lica de Salta. Casta\u00f1ares, 4400, Salta, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Berm\u00fadez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaciones para la Industria Qu\u00edmica, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Antonio","family":"Parada","sequence":"additional","affiliation":[{"name":"Instituto de Patolog\u00eda Experimental, CONICET, Universidad Nacional de Salta. Av. Bolivia 5150, 4400, Salta, Argentina."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1220","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"J. D. Alpern, R. Lopez-Velez, W. M. Stauffer,  \"PLoS Neglected Tropical Diseases.\"  11, \"Access to benznidazole for Chagas disease in the United States\u2014Cautious optimism?\" e0005794 (2017)","DOI":"10.1371\/journal.pntd.0005794"},{"key":"2","doi-asserted-by":"crossref","unstructured":"J. Andersson, A. \u00d6rn, D. Sunnemark,  \"Immunology Letters.\"  86, \"Chronic murine Chagas' disease: The impact of host and parasite genotypes.\" 207 (2003)","DOI":"10.1016\/S0165-2478(03)00019-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"S. G. Andrade,  \"Mem\u00f3rias do Instituto Oswaldo Cruz.\"  85, \"Influence of Trypanosoma cruzi strain on the pathogenesis of chronic myocardiopathy in mice.\" 17 (1990)","DOI":"10.1590\/S0074-02761990000100003"},{"key":"4","doi-asserted-by":"crossref","unstructured":"P. Artursson  and R. T. Borchardt  \"Pharmaceutical Research.\"  14, \"Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond.\" 1655 (1997)","DOI":"10.1023\/A:1012155124489"},{"key":"5","doi-asserted-by":"crossref","unstructured":"L. Bartel, M. Montalto De Mecca, S. Fanelli, et al.  \"Human & Experimental Toxicology.\"  26, \"Early nifurtimox-induced biochemical and ultrastructural alterations in rat heart.\" 781 (2007)","DOI":"10.1177\/0960327107084540"},{"key":"6","doi-asserted-by":"crossref","unstructured":"K. Bonney, D. Luthringer, S. Kim, et al.  \"Annual Review of Pathology.\"  24, \"Pathology and pathogenesis of Chagas heart disease.\" 421 (2019)","DOI":"10.1146\/annurev-pathol-020117-043711"},{"key":"7","doi-asserted-by":"crossref","unstructured":"J. M. Bustamante, J. M. Craft, B. D. Crowe, et al.  \"Journal of Infectious Diseases.\"  209, \"New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.\" 150 (2013)","DOI":"10.1093\/infdis\/jit420"},{"key":"8","unstructured":"J. Castro  and E. G. Diaz De Toranzo  \"Biomedical and Environmental Sciences: BES.\"  1, \"Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease).\" 19 (1988)"},{"key":"9","doi-asserted-by":"crossref","unstructured":"S. G. Castro, S. S. Bruni, C. E. Lanusse, et al.  \"AAPS PharmSciTech.\"  11, \"Improved albendazole dissolution rate in pluronic 188 solid dispersions.\" 1518 (2010)","DOI":"10.1208\/s12249-010-9517-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"\u00c1. C. Cevey, G. A. Mirkin, F. N. Penas, et al.  \"International Journal for Parasitology: Drugs and Drug Resistance.\"  6, \"Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.\" 12 (2016)","DOI":"10.1016\/j.ijpddr.2015.12.001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"W. L. Chiou  and S. Riegelman  \"Journal of Pharmaceutical Sciences.\"  60, \"Pharmaceutical applications of solid dispersion systems.\" 1281 (1971)","DOI":"10.1002\/jps.2600600902"},{"key":"12","doi-asserted-by":"crossref","unstructured":"M. V. P. Coronel, E. C. Mu\u00f1oz, D. K. Valle, et al.  \"Revista da Sociedade Brasileira de Medicina Tropical.\"  50, \"Adverse systemic reaction to benznidazole.\" 145 (2017)","DOI":"10.1590\/0037-8682-0071-2016"},{"key":"13","doi-asserted-by":"crossref","unstructured":"K. L. Cummings  and R. L. Tarleton  \"Molecular and Biochemical Parasitology.\"  129, \"Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR.\" 53 (2003)","DOI":"10.1016\/S0166-6851(03)00093-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"C. Davies, R. M. Cardozo, O. S. Negrette, et al.  \"Antimicrobial Agents and Chemotherapy.\"  54, \"Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.\" 3584 (2010)","DOI":"10.1128\/AAC.01451-09"},{"key":"15","doi-asserted-by":"crossref","unstructured":"C. Davies, N. Dey, O. S. Negrette, et al.  \"PLoS Neglected Tropical Diseases.\"  8, \"Hepatotoxicity in mice of a novel anti-parasite drug candidate hydroxymethylnitrofurazone: A comparison with benznidazole.\" e3231 (2014a)","DOI":"10.1371\/journal.pntd.0003231"},{"key":"16","unstructured":"C. Davies, R. H. Poma, R. M. Cardozo, et al.  \"Acta Bioquimica Clinica Latinoamericana.\"  48, \"Detection of Trypanosoma cruzi in murine blood and tissue by conventional and real time PCR.\" 421 (2014b)"},{"key":"17","doi-asserted-by":"crossref","unstructured":"M. M. De Mecca, L. C. Bartel, C. R. De Castro, et al.  \"Memorias do Instituto Oswaldo Cruz.\"  103, \"Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: Comparison to Nifurtimox-induced cardiac effects.\" 549 (2008)","DOI":"10.1590\/S0074-02762008000600007"},{"key":"18","doi-asserted-by":"crossref","unstructured":"M. M. De Mecca, S. L. Fanelli, L. C. Bartel, et al.  \"Life Sciences.\"  81, \"Nifurtimox nitroreductase activity in different cellular fractions from male rat pancreas. Biochemical and ultrastructural alterations.\" 144 (2007)","DOI":"10.1016\/j.lfs.2007.04.033"},{"key":"19","doi-asserted-by":"crossref","unstructured":"J. De Oliveira Eloy, J. Saraiva, S. De Albuquerque, et al.  \"AAPS PharmSciTech.\"  13, \"Solid dispersion of ursolic acid in gelucire 50\/13: A strategy to enhance drug release and trypanocidal activity.\" 1436 (2012)","DOI":"10.1208\/s12249-012-9868-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"T. Duffy, M. Bisio, J. Altcheh, et al.  \"PLoS Neglected Tropical Diseases.\"  3, \"Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in Chagas disease patients.\" e419 (2009)","DOI":"10.1371\/journal.pntd.0000419"},{"key":"21","doi-asserted-by":"crossref","unstructured":"C. Fonseca-Berzal, R. Palmeiro-Rold\u00e1n, J. A. Escario, et al.  \"Experimental Parasitology.\"  149, \"Novel solid dispersions of benznidazole: Preparation, dissolution profile and biological evaluation as alternative antichagasic drug delivery system.\" 84 (2015)","DOI":"10.1016\/j.exppara.2015.01.002"},{"key":"22","doi-asserted-by":"crossref","unstructured":"A. F. Francisco, S. Jayawardhana, M. D. Lewis, et al.  \"Parasitology.\"  144, \"Biological factors that impinge on Chagas disease drug development.\" 1871 (2017)","DOI":"10.1017\/S0031182017001469"},{"key":"23","doi-asserted-by":"crossref","unstructured":"M. C. Garc\u00eda, M. L. Guzman, M. A. Himelfarb, et al.  \"European Journal of Pharmaceutical Sciences.\"  122, \"Preclinical pharmacokinetics of benznidazole-loaded interpolyelectrolyte complex-based delivery systems.\" 281 (2018a)","DOI":"10.1016\/j.ejps.2018.07.005"},{"key":"24","doi-asserted-by":"crossref","unstructured":"M. C. Garc\u00eda, R. H. Manzo, A. Jimenez-Kairuz,  \"International Journal of Pharmaceutics.\"  545, \"Polysaccharides-based multiparticulated interpolyelectrolyte complexes for controlled benznidazole release.\" 366 (2018b)","DOI":"10.1016\/j.ijpharm.2018.05.017"},{"key":"25","doi-asserted-by":"crossref","unstructured":"M. C. Garc\u00eda, M. Martinelli, N. E. Ponce, et al.  \"European Journal of Pharmaceutical Sciences.\"  120, \"Multi-kinetic release of benznidazole-loaded multiparticulate drug delivery systems based on polymethacrylate interpolyelectrolyte complexes.\" 107 (2018c)","DOI":"10.1016\/j.ejps.2018.04.034"},{"key":"26","doi-asserted-by":"crossref","unstructured":"M. C. Garc\u00eda, N. E. Ponce, L. M. Sanmarco, et al.  \"Antimicrobial Agents and Chemotherapy.\"  60, \"Clomipramine and Benznidazole act synergistically and ameliorate the outcome of experimental Chagas disease.\" 3700 (2016)","DOI":"10.1128\/AAC.00404-16"},{"key":"27","doi-asserted-by":"crossref","unstructured":"R. Iyer, N. Shah, H. Sandhu, et al.  \"Amorphous solid dispersions. Advances in delivery science and technology.\"  , \"Pharmaceutical development of MBP solid dispersions: Case studies.\" 373 (2014)","DOI":"10.1007\/978-1-4939-1598-9_12"},{"key":"28","doi-asserted-by":"crossref","unstructured":"N. Kola\u0161inac, K. Kachrimanis, I. Hom\u0161ek, et al.  \"International Journal of Pharmaceutics.\"  436, \"Solubility enhancement of desloratadine by solid dispersion in poloxamers.\" 161 (2012)","DOI":"10.1016\/j.ijpharm.2012.06.060"},{"key":"29","doi-asserted-by":"crossref","unstructured":"D. Leonardi, M. E. Bombardiere, C. J. Salomon,  \"International Journal of Biological Macromolecules.\"  62, \"Effects of benznidazole: Cyclodextrin complexes on the drug bioavailability upon oral administration to rats.\" 543 (2013)","DOI":"10.1016\/j.ijbiomac.2013.10.007"},{"key":"30","doi-asserted-by":"crossref","unstructured":"D. Leonardi, C. J. Salom\u00f3n, M. C. Lamas, et al.  \"International Journal of Pharmaceutics.\"  367, \"Development of novel formulations for Chagas' disease: Optimization of benznidazole chitosan microparticles based on artificial neural networks.\" 140 (2009)","DOI":"10.1016\/j.ijpharm.2008.09.036"},{"key":"31","doi-asserted-by":"crossref","unstructured":"M. D. Lewis, A. F. Francisco, M. C. Taylor, et al.  \"Cellular Microbiology.\"  18, \"Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy.\" 1429 (2016)","DOI":"10.1111\/cmi.12584"},{"key":"32","doi-asserted-by":"crossref","unstructured":"\u00c1. A. Lima, J. L. Soares-Sobrinho, J. L. Silva, et al.  \"Journal of Pharmaceutical Sciences.\"  100, \"The use of solid dispersion systems in hydrophilic carriers to increase benznidazole solubility.\" 2443 (2011)","DOI":"10.1002\/jps.22436"},{"key":"33","doi-asserted-by":"crossref","unstructured":"C. Mary, F. Faraut, L. Lascombe, et al.  \"Journal of Clinical Microbiology.\"  42, \"Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity.\" 5249 (2004)","DOI":"10.1128\/JCM.42.11.5249-5255.2004"},{"key":"34","doi-asserted-by":"crossref","unstructured":"F. P. Maximiano, G. H. Y. Costa, J. De Souza, et al.  \"Qu\u00edmica Nova.\"  33, \"Physicochemical characterization of antichagasic benznidazole.\" 1714 (2010)","DOI":"10.1590\/S0100-40422010000800018"},{"key":"35","doi-asserted-by":"crossref","unstructured":"L. Mayol, F. Quaglia, A. Borzacchiello, et al.  \"European Journal of Pharmaceutics and Biopharmaceutics.\"  70, \"A novel poloxamers\/hyaluronic acid in situ forming hydrogel for drug delivery: Rheological, mucoadhesive and in vitro release properties.\" 199 (2008)","DOI":"10.1016\/j.ejpb.2008.04.025"},{"key":"36","doi-asserted-by":"crossref","unstructured":"C. A. Morillo, J. A. Marin-Neto, A. Avezum, et al.  \"New England Journal of Medicine.\"  373, \"Randomized trial of benznidazole for chronic Chagas' cardiomyopathy.\" 1295 (2015)","DOI":"10.1056\/NEJMoa1507574"},{"key":"37","doi-asserted-by":"crossref","unstructured":"F. Nagajyothi, F. S. Machado, B. A. Burleigh, et al.  \"Cellular Microbiology.\"  14, \"Mechanisms of Trypanosoma cruzi persistence in Chagas Disease.\" 634 (2012)","DOI":"10.1111\/j.1462-5822.2012.01764.x"},{"key":"38","unstructured":"et al.  \"Guide for the care and use of laboratory animals.\"  , 248 (2011)"},{"key":"39","doi-asserted-by":"crossref","unstructured":"O. S. Negrette, F. J. S. Vald\u00e9z, C. D. Lacunza, et al.  \"Clinical and Vaccine Immunology.\"  15, \"Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease.\" 297 (2008)","DOI":"10.1128\/CVI.00106-07"},{"key":"40","doi-asserted-by":"crossref","unstructured":"A. Newman, G. Knipp, G. Zografi,  \"Journal of Pharmaceutical Sciences.\"  101, \"Assessing the performance of amorphous solid dispersions.\" 1355 (2012)","DOI":"10.1002\/jps.23031"},{"key":"41","doi-asserted-by":"crossref","unstructured":"M. J. Olivera, Z. M. Cucunub\u00e1, C. A. Valencia-Hern\u00e1ndez, et al.  \"PloS One.\"  12, \"Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease.\" e0185033 (2017)","DOI":"10.1371\/journal.pone.0185033"},{"key":"42","doi-asserted-by":"crossref","unstructured":"R. Palmeiro-Rold\u00e1n, C. Fonseca-Berzal, A. G\u00f3mez-Barrio, et al.  \"International Journal of Pharmaceutics.\"  472, \"Development of novel benznidazole formulations: Physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease.\" 110 (2014)","DOI":"10.1016\/j.ijpharm.2014.06.015"},{"key":"43","doi-asserted-by":"crossref","unstructured":"J. A. P\u00e9rez-Molina  and I. Molina  \"Lancet.\"  391, \"Chagas disease.\" 82 (2018)","DOI":"10.1016\/S0140-6736(17)31612-4"},{"key":"44","doi-asserted-by":"crossref","unstructured":"JR., A. Rassi, A. Rassi, J. A. Marin-Neto,  \"Lancet.\"  375, \"Chagas Disease.\" 1388 (2010)","DOI":"10.1016\/S0140-6736(10)60061-X"},{"key":"45","doi-asserted-by":"crossref","unstructured":"M. S. Rial, M. L. Scalise, E. C. Arr\u00faa, et al.  \"PLoS Neglected Tropical Diseases.\"  11, \"Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.\" e0006119 (2017)","DOI":"10.1371\/journal.pntd.0006119"},{"key":"46","doi-asserted-by":"crossref","unstructured":"H. F. Santos Souza, D. Real, D. Leonardi, et al.  \"Tropical Medicine & International Health.\"  22, \"Development and in vitro\/in vivo evaluation of a novel benznidazole liquid dosage form using a quality-by-design approach.\" 1514 (2017)","DOI":"10.1111\/tmi.12980"},{"key":"47","unstructured":"L. Savioli  and D. Daumerie  \"Sustaining the drive to overcome the global impact of neglected tropical diseases: Second WHO report on neglected tropical diseases.\"  , 153 (2013)"},{"key":"48","doi-asserted-by":"crossref","unstructured":"M. L. Scalise, E. C. Arr\u00faa, M. S. Rial, et al.  \"American Journal of Tropical Medicine and Hygiene.\"  95, \"Promising efficacy of benznidazole nanoparticles in acute Trypanosoma cruzi murine model: In-vitro and in-vivo studies.\" 388 (2016)","DOI":"10.4269\/ajtmh.15-0889"},{"key":"49","doi-asserted-by":"crossref","unstructured":"M. Segura, E. Raspi, M. Basombrio,  \"Memorias do Instituto Oswaldo Cruz.\"  89, \"Reversibility of muscle and heart lesions in chronic Trypanosoma cruzi infected mice after late trypanomicidal treatment.\" 213 (1994)","DOI":"10.1590\/S0074-02761994000200017"},{"key":"50","doi-asserted-by":"crossref","unstructured":"A. Simonazzi, C. Davies, A. G. Cid, et al.  \"Journal of Pharmaceutical Sciences.\"  11, \"Preparation and characterization of Poloxamer 407 solid dispersions as an alternative strategy to improve benznidazole bioperformance.\" 2829 (2018)","DOI":"10.1016\/j.xphs.2018.06.027"},{"key":"51","unstructured":"S. Sosa Estani, J. Altcheh, A. Riarte, et al.  \"Medicina (Buenos Aires).\"  75, \"Lineamientos b\u00e1sicos del tratamiento etiol\u00f3gico de enfermedad de Chagas.\" 270 (2015)"},{"key":"52","doi-asserted-by":"crossref","unstructured":"J. A. Urbina,  \"Journal of Eukaryotic Microbiology.\"  62, \"Recent clinical trials for the etiological treatment of chronic Chagas disease: Advances, challenges and perspectives.\" 149 (2015)","DOI":"10.1111\/jeu.12184"},{"key":"53","doi-asserted-by":"crossref","unstructured":"E. Van Santen, D. Barends, H. Frijlink,  \"European Journal of Pharmaceutics and Biopharmaceutics.\"  53, \"Breaking of scored tablets: A review.\" 139 (2002)","DOI":"10.1016\/S0939-6411(01)00228-4"},{"key":"54","doi-asserted-by":"crossref","unstructured":"C. Vergara, G. Mu\u00f1oz, G. Mart\u00ednez, et al.  \"PLoS One.\"  8, \"Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox.\" e0221100 (2019)","DOI":"10.1371\/journal.pone.0221100"},{"key":"55","unstructured":"E. Villiers  and L. Blackwood  \"BSAVA manual of canine and feline clinical pathology.\"  , 300 (2005)"},{"key":"56","doi-asserted-by":"crossref","unstructured":"R. Viotti, B. A. De Noya, T. Araujo-Jorge, et al.  \"Antimicrobial Agents and Chemotherapy.\"  58, \"Towards a paradigm shift in the treatment of chronic Chagas disease.\" 635 (2014)","DOI":"10.1128\/AAC.01662-13"},{"key":"57","doi-asserted-by":"crossref","unstructured":"P. Workman, R. White, M. Walton, et al.  \"British Journal of Cancer.\"  50, \"Preclinical pharmacokinetics of benznidazole.\" 291 (1984)","DOI":"10.1038\/bjc.1984.176"},{"key":"58","unstructured":"et al.  \"World Health Organization technical report series.\"  , \"Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis.\" 116 (2012)"},{"key":"59","doi-asserted-by":"crossref","unstructured":"B. Zingales, S. G. Andrade, M. R. S. Briones, et al.  \"Memorias do Instituto Oswaldo Cruz.\"  104, \"A new consensus for Trypanosoma cruzi intraspecific nomenclature: Second revision meeting recommends TcI to TcVI.\" 1051 (2009)","DOI":"10.1590\/S0074-02762009000700021"}],"container-title":["Journal of Parasitology"],"original-title":[],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T09:16:33Z","timestamp":1588151793000},"score":1,"resource":{"primary":{"URL":"https:\/\/bioone.org\/journals\/journal-of-parasitology\/volume-106\/issue-3\/19-80\/Benznidazole-Poloxamer-407-Solid-Dispersion-as-a-New-Strategy-to\/10.1645\/19-80.full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1645\/19-80","relation":{},"ISSN":["0022-3395"],"issn-type":[{"value":"0022-3395","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,4]]}}}